OVID Ovid Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: OVID

Price (delayed)

$2.57

Market cap

$501.92M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.23

Enterprise value

$502.24M

?
Relative Growth: Rel. Growth: 27
Relative Strength: Rel. Strength: 86
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 37

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company dedicated to developing medicines for brain conditions with significant unmet need. The Company is advancing a pipeline of novel, targeted small ...

Highlights
OVID's quick ratio has soared by 165% YoY and by 19% QoQ
OVID's equity is up by 6% from the previous quarter
The EPS has soared by 57% YoY but it is down by 10% QoQ
The net income has contracted by 43% from the previous quarter but it has grown by 10% YoY
OVID's revenue has dropped by 78% since the previous quarter and by 76% year-on-year
The gross profit has plunged by 78% from the previous quarter and by 76% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.ovidrx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of OVID

OVID stock price

How has the Ovid Therapeutics stock price performed over time
Intraday
-6.88%
1 week
-4.1%
1 month
-8.21%
1 year
103.97%
YTD
57.67%
QTD
-4.46%

Financial performance

How have Ovid Therapeutics's revenue and profit performed over time
Revenue
$1.58M
Gross profit
$1.58M
Operating income
-$58.36M
Net income
-$34.49M
Gross margin
100%
Net margin
-2,178.9%
OVID's revenue has dropped by 78% since the previous quarter and by 76% year-on-year
The gross profit has plunged by 78% from the previous quarter and by 76% YoY
The net income has contracted by 43% from the previous quarter but it has grown by 10% YoY
The operating income has declined by 40% year-on-year and by 22% since the previous quarter

Price vs fundamentals

How does OVID's price correlate with its fundamentals

Growth

What is Ovid Therapeutics's growth rate over time

Valuation

What is Ovid Therapeutics stock price valuation
P/E
N/A
P/B
2.29
P/S
320.57
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
317.27
The EPS has soared by 57% YoY but it is down by 10% QoQ
OVID's price to book (P/B) is 75% more than its 5-year quarterly average of 1.4 and 44% more than its last 4 quarters average of 1.7
OVID's equity is up by 6% from the previous quarter
OVID's revenue has dropped by 78% since the previous quarter and by 76% year-on-year
OVID's price to sales (P/S) is 18% more than its 5-year quarterly average of 291.2

Efficiency

How efficient is Ovid Therapeutics business performance
Ovid Therapeutics's ROE has soared by 60% YoY but it has decreased by 4.9% from the previous quarter
OVID's ROIC has soared by 54% YoY and by 2.3% QoQ
The return on assets has surged by 53% year-on-year but it has declined by 10% since the previous quarter

Dividends

What is OVID's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OVID.

Financial health

How did Ovid Therapeutics financials performed over time
Ovid Therapeutics's total assets has soared by 200% YoY and by 2.8% from the previous quarter
OVID's quick ratio has soared by 165% YoY and by 19% QoQ
Ovid Therapeutics's debt is 94% lower than its equity
Ovid Therapeutics's debt to equity has plunged by 76% YoY and by 14% from the previous quarter
OVID's equity is up by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.